Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Adicet Bio Inc (NQ: ACET )

1.400 +0.060 (+4.48%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 245,932
Open 1.350
Bid (Size) 1.390 (19)
Ask (Size) 1.400 (14)
Prev. Close 1.340
Today's Range 1.350 - 1.420
52wk Range 1.050 - 3.770
Shares Outstanding 42,957,586
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
ADI-001 Clinical Biomarker Data Demonstrate Robust Tissue Trafficking and Complete B Cell Depletion in Secondary Lymphoid Tissue
From Adicet Bio, Inc.
Via Business Wire
This Novartis Analyst Is No Longer Bullish; Here Are Top Downgrades For Wednesday
Via Benzinga

Performance

YTD
-30.35%
-30.35%
1 Month
-8.50%
-8.50%
3 Month
+4.48%
+4.48%
6 Month
-39.91%
-39.91%
1 Year
-2.10%
-2.10%

More News

Read More
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Adicet Bio, Inc.
Via Business Wire
Adicet Bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference
From Adicet Bio, Inc.
Via Business Wire
Adicet Bio Appoints Lloyd Klickstein, M.D., Ph.D. to the Board of Directors
From Adicet Bio, Inc.
Via Business Wire
ACET Stock Earnings: Adicet Bio Beats EPS for Q2 2024
Via InvestorPlace
Adicet Reports Second Quarter 2024 Financial Results and Provides Business Updates
From Adicet Bio, Inc.
Via Business Wire
Adicet Bio to Participate in Upcoming Investor Conferences
From Adicet Bio, Inc.
Via Business Wire
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Adicet Bio, Inc.
Via Business Wire
Adicet Bio Receives FDA Fast Track Designation for ADI-270 in Metastatic/Advanced Clear Cell Renal Cell Carcinoma
From Adicet Bio, Inc.
Via Business Wire
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Adicet Bio, Inc.
Via Business Wire
Adicet Bio Announces FDA Clearance of IND Application for ADI-270 in Renal Cell Carcinoma
From Adicet Bio, Inc.
Via Business Wire
Under-$10 Picks: 3 Biotech Stocks That Can Double Before the End of 2024
Via InvestorPlace
Adicet Bio Receives FDA Fast Track Designation for ADI-001 in Lupus Nephritis
From Adicet Bio, Inc.
Via Business Wire
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Adicet Bio, Inc.
Via Business Wire
Adicet Bio to Participate in a Fireside Chat at the 2024 Jefferies Healthcare Conference
From Adicet Bio, Inc.
Via Business Wire
ACET Stock Earnings: Adicet Bio Beats EPS for Q1 2024
Via InvestorPlace
Adicet Reports First Quarter 2024 Financial Results and Provides Business Updates
From Adicet Bio, Inc.
Via Business Wire
Adicet Bio Announces Poster Presentation of ADI-270 Preclinical Data at the 2024 European Hematology Association (EHA) Hybrid Congress
From Adicet Bio, Inc.
Via Business Wire
Adicet Bio to Participate in a Fireside Chat at the Citizens JMP Life Sciences Conference
From Adicet Bio, Inc.
Via Business Wire
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
From Adicet Bio, Inc.
Via Business Wire
Adicet Bio Highlights Preclinical Data Supporting IND Readiness for ADI-270 in an Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting
From Adicet Bio, Inc.
Via Business Wire
Adicet Bio to Participate in 2024 Canaccord Genuity Horizons in Oncology Virtual Conference
From Adicet Bio, Inc.
Via Business Wire
Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
From Adicet Bio, Inc.
Via Business Wire
The Penny Stock A-List: 7 High-Profile Companies on the Verge of Greatness
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.